Zydus Wellness Ltd Share Price (ZYDUSWELL)

Zydus Lifesciences Receives 10 Observations from USFDA - 24 Apr, 2024

The US Food and Drug Administration (USFDA) has issued ten observations after inspecting Zydus Lifesciences' injectable manufacturing plant near Vadodara in Gujarat. The company will work closely with the USFDA to address and respond to the observations.

Zydus Launches New Drug and Receives Approval for Another in China - 23 Apr, 2024

Zydus Lifesciences has launched a new drug, Mirabegron extended-release tablets, in the US market for the treatment of overactive bladder. Additionally, the National Medical Products Administration of China (NMPA) has accepted the company's new drug application (NDA) for Desidustat Tablets used to treat anaemia in chronic kidney disease patients.

Zydus Launches Generic Drug in US Market, Receives Marketing Authorization in GB - 22 Apr, 2024

Zydus Lifesciences has launched a generic medication to treat overactive bladder in the US market and received marketing authorization for Nulibry in Great Britain. The launch of the generic drug is expected to strengthen Zydus' growth plans in the US market.

Zydus Subsidiary Receives Marketing Authorization for NULIBRY - 20 Apr, 2024

Zydus Lifesciences' subsidiary, Sentynl Therapeutics, has received marketing authorization from the UK MHRA for NULIBRY as the first therapy for MoCD Type A. This is a significant milestone in treating an ultra-rare genetic disorder that impacts fewer than 150 patients globally.

Zydus Wellness Reports Strong Revenue Growth in FY23 - 16 Apr, 2024

Zydus Wellness reported a strong growth in revenue for FY23 and has a lower P/E ratio compared to the industry average. La Renon joined ChrysCapital's list of Indian healthcare companies which includes Zydus Cadila.

Health Food Drinks Market in India Worth Over $1 Billion - 15 Apr, 2024

Zydus Wellness' Complan is one of the popular health food drinks in India, marketed as a nutritional drink. The market for such malt-based milk drinks has been growing steadily and is worth over $1 billion.

Zydus Lifesciences Receives Four Observations from USFDA After Inspection - 28 Mar, 2024

Zydus Lifesciences receives four observations from the USFDA following an inspection of its Onco Injectable manufacturing plant in Ahmedabad. Despite this, the company's share price remains stable as it posts a strong financial performance in Q1-Q3 FY24.

Zydus Lifesciences Receives Observations from USFDA - 27 Mar, 2024

The US Food and Drug Administration (USFDA) has issued four observations to Zydus Lifesciences' SEZ Onco Injectable manufacturing plant in Ahmedabad. The company will work closely with the USFDA to address and resolve the observations.

Zydus Lifesciences Shares Surge on FDA Approval - 26 Mar, 2024

Zydus Lifesciences' stock value surges as it receives tentative approval from the US Food and Drug Administration (FDA) for its Letermovir tablets, used to prevent disease caused by a virus called cytomegalovirus. The approval marks a major milestone for Zydus Lifesciences and signals sustained investor confidence.